Day: March 12, 2024

TORONTO, March 12, 2024 (GLOBE NEWSWIRE) — Quisitive Technology Solutions, Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a trusted Microsoft solutions provider and three-time Microsoft Healthcare Partner of the Year award winner, is proud to announce the upcoming launch of MazikCare copilot, a ground-breaking AI-powered healthcare solution set to redefine collaboration and productivity in the healthcare industry. Previewing at the annual HIMSS conference in Orlando, Florida, this week from March 11-15. MazikCare copilot is scheduled for general release in April 2024 and represents a significant leap forward in care coordination. Addressing Critical Challenges in Healthcare In today’s healthcare landscape, physicians and care teams face an overwhelming burden of administrative tasks, contributing to burnout and...

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today announced that the United States Department of Transportation (“DoT”) recently granted Special Permit 21693 and Special Permit 21704 to the Company. The new special permits cover transportation of damaged, defective, or recalled (“DDR”) batteries as well as end-of-life (“EOL”) batteries to include the critical area of battery disposal and recycling, paving the way for safer and more sustainable battery recovery and reuse practices. The DoT’s approval of these special permits validates the safety standards and reliability of KULR’s SafeCASE™ product for transporting and storing lithium-ion batteries which is expected...

Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing Technology First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, and Arbor Biotechnologies, Inc. (“Arbor”), a biotechnology company discovering and developing the next generation of genetic medicines, today announced a non-exclusive, global gene editing licensing agreement for use of Arbor’s proprietary CRISPR gene-editing technology in Allogene’s next generation AlloCAR T platform for the treatment of autoimmune...

3D Systems’ DMP Flex 350 Dual3D Systems’ DMP Flex 350 DualAddition of single and dual laser printers enables use of broader materials portfolio to address new applications with Titanium, Stainless Steel DMP Flex 350’s best-in-class oxygen level (

SEATTLE, March 12, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that Tessa Cigler, M.D., M.P.H. was appointed to Atossa’s board of directors, effective immediately. Dr. Cigler is a medical oncologist and clinical investigator at the Weill Cornell Breast Center in New York City. “We are pleased to welcome Dr. Cigler to our board of directors,” said Steven Quay, M.D., Ph.D., Atossa’s President and Chief Executive Officer. “Tessa works daily with breast cancer patients and knows firsthand the critical need for more effective and tolerable treatment options. We look forward to leveraging both her clinical trial...

LOS ALAMITOS, Calif. and LAS VEGAS, March 12, 2024 (GLOBE NEWSWIRE) — Verb Technology Company, Inc. (Nasdaq: VERB) (“VERB” or the “Company”), continues the expansion of its MARKET.live livestream social shopping platform with the addition of FIFTY more innovative brands. Discover the Latest Brands to join MARKET.live: Joya Mia  DAWGS USA  A bit unique boutique  Mr. Woodware  Four Points Trading Co.  Quality Home Distribution  Massiell Made  The Barkery Long Island  gymsegbë  Cimarron Creek Essentials  LashBeePro  Mountain Goat Soap Co.  tabbeauplace  Artius Man  Meta Skin Studio  Axiology  Ora’s Amazing Herbal  S E E K E R  TeamKeto  Ritual Zero Proof  FarmHouse Fresh  ALODERMA  Medusa’s Makeup  Lash Affair  Sally B’s Skin Yummies  Florida Glow  GladGirl  M.S. Skincare  LastObject  Profusion...

CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a conference session investors can attend in person, or via webcast. Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and time: March 18, 2024 at 3:00 pm PDT Location: The Ritz-Carlton, Laguna NiguelWebcast: Click here Tenax Therapeutics’ management will also participate...

Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) — SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, provides updates on the acute kidney injury (AKI) programs it is developing with its patented, first-to-market, cell-directed Selective Cytopheretic Device (SCD) extracorporeal therapy in critically ill patients with AKI. “We now have 21 subjects enrolled across five clinical sites in our NEUTRALIZE-AKI pivotal clinical trial, which is intended to evaluate the safety and efficacy of our SCD in adult AKI patients. Additional sites are progressing through the site activation and contract completion process,” said Kevin Chung, MD, Chief Medical...